Emerging treatments, collaboration between health care providers, and new policy proposals have led to a positive outlook for the future of nonalcoholic steatohepatitis (NASH) and its treatment.
Global Liver Institute | Strategic Alliance Partners
Latest from Global Liver Institute
Jeff J, Mclntyre, MA, Vice President of Liver Health Programs, Global Liver Institute, discussed the clinical and economic burden of NASH
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
5
